PA
CRESY

PharVision Advisers’s Cresud CRESY Stock Holding History

PharVision Advisers’s Portfolio CRESY Stock Details CRESY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,046
Closed -$228K – 229
2025
Q4 		$228K Buy
18,046
+3,287
+22% +$36.4K 0.12% 453
2025
Q3 		$135K Buy
+14,759
New +$152K 0.08% 587

Other funds holding CRESY

KGI
Kopernik Global Investors Tampa, Florida $1.43B AUM 63.57% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
S
Systrade Vaduz, Liechtenstein $160M AUM 73.26% 1-Year Est. Return
Mirae Asset Global ETFs Holdings
Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return
CCP
Crocodile Capital Partners Ursensollen, Germany $147M AUM 67.67% 1-Year Est. Return
VAS
VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $1.72B AUM 91.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

PharVision Advisers's CRESY Position: Q1 2026 in Review

PharVision Advisers sold out of Cresud (CRESY) in Q1 2026, closing a stake of 18,046 shares — an estimated $228K sold.

PharVision Advisers first reported a position in CRESY in Q3 2025 and held it in 2 quarters. The position peaked at $228K in Q4 2025. 64 funds tracked by Wall St. Rank hold CRESY as of Q1 2026.

  • PharVision Advisers reported no remaining Cresud position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 18,046 Cresud shares in Q1 2026, an estimated $228K.
  • PharVision Advisers first reported a position in Cresud in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Cresud position peaked at $228K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Cresud as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.